Twitter Logo Youtube Circle Icon LinkedIn Icon

United States > Industry focus > Healthcare: life sciences > Law firm and leading lawyer rankings


Index of tables

  1. Healthcare: life sciences
  2. Hall of Fame
  3. Leading lawyers
  4. Next generation lawyers

Leading lawyers

  1. 1

Next generation lawyers

  1. 1

Who Represents Who

Find out which law firms are representing which Healthcare: life sciences clients in United States using The Legal 500's new comprehensive database of law firm/client relationships. Instantly search over 925,000 relationships, including over 83,000 Fortune 500, 46,000 FTSE350 and 13,000 DAX 30 relationships globally. Access is free for in-house lawyers, and by subscription for law firms. For more information, contact


Considered among the ‘go-to’ firms in the industry, Hogan Lovells US LLP’s practice excels in handling regulatory and corporate transactions, as well as IP matters. The practice’s litigation expertise was strengthened following the firm’s merger with Collora. In Baltimore, global chair Asher Rubin led advice to Pfizer as an investor in the SpringWorks Therapeutics venture regarding the development of new healthcare projects. In New York, the well-regarded Adam Golden has been advising Valeant Pharmaceuticals on all aspects of the $820m sale of Dendreon Pharmaceuticals to Sanpower Group. In Washington DC, regulatory experts Philip Katz and James Johnson have been assisting Chinese pharmaceutical manufacturer Hisun Pharmaceuticals with Food and Drug Administration (FDA) and compliance issues. Other names to note are David Fox in Washington DC, as well as Janice Hogan and Susan Lee in Philadelphia. The practice was significantly strengthened by the arrival of former Weil, Gotshal & Manges LLP M&A lawyers Keith Flaum, Richard Climan and Jane Ross in Silicon Valley, as well as technology expert John Brockland in San Francisco. Jason Hadges, David Horowitz, Edith Ramirez and Patricia Shrader joined the Washington DC office from the DEA, HHS, FTC and Medtronic, respectively. Jennifer Henderson and Christopher Schott were promoted to partner in Washington DC, while Michael Szlamkowicz was promoted to partner in New York. Washington DC-based Kristin Duggan is now of counsel. Anishiya Abrol is also a name to note in Washington DC.

Arnold & Porter’s ‘go-to’ department often acts for high-profile pharmaceutical companies on all aspects of life sciences matters, including transactions, litigation and regulatory issues. In New York, the well-regarded Anand Agneshwar has been leading advice to Bristol-Myers Squibb on various product liability matters regarding the company’s drug Plavix. Jeffrey Handwerker continued to represent the Pharmaceutical Research and Manufacturers of America in various contentious and non-contentious matters, including issues arising from potential changes to legislation regarding pricing. IP specialist David Marsh has been advising Shumway Capital on both domestic and international patent prosecution and procurement matters. William Hoffman and Pamela Yates have been defending Bayer in a product liability dispute regarding the client’s Xarelto medicine. Co-chaired by Daniel Kracov and Allison Shuren, the department includes Ariane Horn, Mahnu Davar and Matthew Wolf, and was strengthened by the arrival of Steve Benz from Eli Lilly. All partners are based in Washington DC unless otherwise stated.

At Latham & Watkins LLP, the department has considerable expertise handling both domestic and international matters for high-profile clients. In Washington DC, regulatory expert John Manthei has been leading advice to Pacira Pharmaceuticals on various issues arising from a warning letter issued by the FDA in 2014, including Department of Justice (DOJ) investigations. Also in Washington DC, Michael Morin and David Frazier have been representing AbbVie in a number of suits brought against Gilead Sciences regarding allegations of infringement. On the M&A side, Silicon Valley-based Alan Mendelson led advice to Rapidscan Pharma Solutions on its sale to GE Medical Systems. The department includes Mark Roeder and Josh Dubofsky in Silicon Valley; Charles Ruck and R Scott Shean in Orange County; and Daniel Brown in New York. Judith Hasko and Alice Fisher in Silicon Valley are also recommended, as is Boston-based Peter Handrinos. Casey Dwyer is now at AbbVie.

Ropes & Gray LLP’s team often advises clients on high-profile corporate and litigation matters. Co-chair Gregory Levine, along with Zach Blume and Paul Kinsella, led advice to Aegerion Pharmaceuticals on various contentious and non-contentious issues, including the negotiation of a consent decree with the FDA and DOJ. Michael Beauvais assisted Bain Capital with a $55m financing and investment round for German biopharmaceutical company InflaRx. David McIntosh acted for Akebia Therapeutics on various corporate transactions, including a number of major licensing agreements. The team, which includes the well-regarded Steven Wilcox, Mark Bellomy and Marc Rubenstein, was bolstered by the arrivals of Paul Scrivano in San Francisco from O'Melveny & Myers LLP and David Blittner in New York from Weil, Gotshal & Manges LLP. All partners are based in Washington DC and Boston unless otherwise stated.

Cooley LLP’s practice has considerable strength handling matters for start-ups and emerging companies. It is led by Palo Alto-based Barbara Kosacz, who often advises clients on a wide range of corporate transactions, including collaborations, financings and IPOs. New York-based Ivor Elrifi specializes in patent prosecution, licensing and transactional work, among other IP-related matters. In Silicon Valley, Mika Reiner Mayer has particular expertise assisting life sciences companies, as well as investors, with due diligence matters. Other names to note are Jeffrey Libson, Geoffrey Starr and Manya Deehr in Princeton, as well as Wendy Goldstein in New York and Michael Tuscan in Washington DC.

The ‘excellent’ Boston-based group at Goodwin has notable transactional capabilities. Co-head Kingsley Taft advised Warp Drive Bio on the company’s strategic collaboration with Roche valued at $387m. Co-head Mitchell Bloom represented Ablynx in various matters arising from the company’s $200m IPO. Scott Lassman has been acting for Boehringer Ingelheim on various issues arising from a citizen petition filed with the FDA. Other names to note are Richard Hoffman, as well as Hatch-Waxman litigation specialists Daryl Wiesen and David Hashmall. The group was strengthened by the arrivals of Roger Cohen in New York from Proskauer Rose LLP and Catherine McCarthy in Boston from Lando & Anastasi. Seo Salimi and William Collins were promoted to partner in the New York and Boston offices, respectively. Named attorneys are based in Boston unless otherwise stated. In April 2018, Kristopher Brown joined in New York from Dechert LLP.

King & Spalding LLP’s multidisciplinary practice handles a wide range of contentious and non-contentious matters for clients in the industry, including FDA and IP issues and high-profile corporate transactions. Co-head Nikki Reeves, Lisa Dwyer, Jeffrey Bucholtz and Sheldon Bradshaw led advice to Egalet on an FDA issue regarding the company’s Arymo ER drug. Co-head Christina Markus defended a pharmaceutical and medical device distributor against claims brought by the California State Board of Pharmacy alleging violation of state requirements for wholesale distributor licenses. In San Francisco, Thomas Duley was engaged by Dermira on various matters arising from a license agreement with Hoffmann-La Roche. The practice is also led by Mark Brown, David Farber and Seth Lundy. Other names to note are Andrew Bayman and John Harris in Atlanta, Peter Strotz in Los Angeles, Donald Zimmer and Stephen Abreu in San Francisco, and Preeya Noronha Pinto in Washington DC. The team was strengthened by the arrival of Joseph Diamante and Charles Cantine from Stroock & Stroock & Lavan LLP in New York. Partners are based in Washington DC unless otherwise stated.

The ‘tremendous’ team at Morgan, Lewis & Bockius LLP is known for its ‘unmatched legal analysis’ and has notable experience handling contentious and non-contentious matters with an international element. Princeton-based co-head Randall Sunberg led advice to Merck on the negotiation of a clinical co-development agreement with Avillion regarding various late-stage pharmaceutical products. On the litigation side, Chicago-based Michael Abernathy represented Praxair in district court litigation arising from a number of patent infringement disputes regarding the use of Inomax. In Washington DC, Elizabeth Bierman led advice on the regulatory aspects of Valeritas’ $50m public offering; Emilio Ragosa and Steven Cohen in Princeton led on the transactional side. Kathleen Sanzo and Jeffry Mann also lead the team from Washington DC and San Francisco, respectively. Michele Buenafe in Washington DC and Alan Leeds in Princeton are key names. In February 2018, Tony Chan joined in Washington DC from Dechert LLP.

DLA Piper LLP (US)’s ‘excellent, responsive and knowledgeable’ department has considerable experience assisting high-profile clients with regulatory, transactional and IP matters, as well as complex global disputes. San Diego-based co-head Lisa Haile and New York-based Stuart Pollack have been leading advice to SteadyMed on various patent invalidation claims brought against United Therapeutics before the Patent Trial and Appeal Board (PTAB). Co-head Richard Mulloy and Drew Wintringham, who are in San Diego and New York, respectively, have been representing Covidien in patent litigation brought against Ethicon arising from the release of Ethicon’s Enseal X1 medical device. The team also acted for Sanpower Group on its $820m acquisition of Dendreon Pharmaceuticals. Also led by product liability expert Matthew Holian in Boston, the team includes George Karavetsos in Miami, Loren Brown in New York, Raymond Williams in Philadelphia, Larry Nishnick in San Diego and Aaron Fountain, who splits his time between Austin and Houston.

At Dechert LLP, the group is known for its expertise in patent litigation, as well as regulatory and transactional matters. In Philadelphia, George Gordon, who specializes in antitrust matters, has been defending Lannett Company against price-fixing claims, while Martin Black successfully represented Svenska Cellulosa (SCA) in a patent infringement dispute regarding the client’s hygiene product. Boston-based practice co-chair Andrea Reid assisted Nimbus Therapeutics with the development and implementation of a patent portfolio strategy regarding a program for patients with autoimmune disorders. The group is also led by New York-based David Rosenthal and also includes David Schulman in Washington DC.

Trusted Advisor - with Finnegan

IP specialist Finnegan detail how their collaborative approach makes for a unique culture which is designed to allow them to work with clients in a way which is cognizant of the challenges facing all companies today.

Foley & Lardner LLP’s department has considerable strength handling the IP-related aspects of both contentious and non-contentious matters. Co-chair David Rosen specializes in FDA matters. Stephen Maebius often advises clients on patent matters, including due diligence and infringement issues. In San Francisco, Judith Waltz has significant experience assisting clients with government investigations and bankruptcy matters. San Diego-based Beni Surpin often handles both domestic and international transactions, including collaborations. Other names to note are Richard Kaufman in San Diego and Andrew Hurst in Washington DC. All partners are based in Washington DC unless otherwise stated.

Knowledgeable, responsive and strategic’, Jones Day’s practice often advises clients on complex corporate and litigation matters with an international element. San Diego-based global IP practice head Anthony Insogna, Cleveland-based Calvin Griffith and Atlanta-based Stephanie Parker successfully assisted Idenix Pharmaceuticals with obtaining a jury verdict in a patent infringement case brought against Gilead Sciences regarding an ingredient in a number of Gilead’s drugs. Healthcare group co-head Maureen Bennett, who splits her time between Boston and San Francisco, and San Diego-based John Beeson advised Dainippon Sumitomo Pharma on its high-profile acquisition of Tolero Pharmaceuticals. Key names include co-head Stephen Sozio in Cleveland and Kevin Espinola in Irvine. The practice saw a number of movements with the arrivals of Ann Hollenbeck in Detroit from Honigman Miller Schwartz and Cohn LLP and Adam Rogers in Miami from DLA Piper LLP (US). Patricia Campbell and Claire Castles were promoted to partner in the Silicon Valley and Los Angeles offices, respectively.

The team at McDermott Will & Emery LLP has experience representing clients in domestic and cross-border litigation. In Boston, Byron Kalogerou and Albert Sokol led advice to Neurovance on its high-profile acquisition by Japanese pharmaceutical company Otsuka Pharmaceutical. Silicon Valley-based William Gaede has been defending Ambry Genetics against patent infringement allegations brought by Esoterix and Johns Hopkins University regarding a number of Ambry’s products. Also in Silicon Valley, Paul DeStefano acted for Eutilex on an agreement with Zhejiang Huahai Pharmaceutical. Chicago-based practice co-chair Kristian Werling is also recommended.

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.’s Boston-based multidisciplinary group handles the full range of contentious and non-contentious matters for life sciences clients, including antitrust, corporate and enforcement issues. Co-chair Jonathan Kravetz also leads on securities and capital market matters. Co-chair William Whelan often advises clients in the technology arena, including biotechnology and healthcare IT. Senior counsel Jeffrey Wiesen has experience acting for clients ranging from start-ups to major public companies in complex domestic and international transactions.

Norton Rose Fulbright US LLP’s ‘excellent’ team has significantly increased its ‘great industry knowledge’ following its merger with Chadbourne & Parke. In New York, Andres Liivak led advice to Novartis on licensing issues regarding the company’s ECF843 eye drops. In Washington DC, Marilyn Mooney has been assisting Bayer with the US aspects of the €1bn divestiture of its diabetes care business to Panasonic Healthcare. Jointly headed by Yvonne Puig in Austin and Frederick Robinson in Washington DC, the team includes IP partners Charles Walker in Houston and Gina Shishima in Austin, as well as Frederick Robinson and Lesley Reynolds in Washington DC, and Steven Suzzan in New York. Other clients include Boston Scientific, Sanofi and GSK.

Reed Smith LLP’s group has significant expertise assisting clients with a wide range of transactions, including M&A and collaboration agreements. In Princeton, co-head Diane Frenier and Betty Yan led advice to a development stage company on negotiations arising from a collaborative license agreement with a pharmaceutical company regarding the development and commercialization of the client’s eye treatment drug. Frenier also assisted a pharmaceutical company with its acquisition of an exclusive license of a new vaccine technology. The group, which is also led by Melissa Geist in Princeton, was strengthened by the arrivals of Rachael Pontikes from Duane Morris LLP and Bryan Webster from McDermott Will & Emery LLP in the firm’s Chicago office. In Philadelphia, Jonathan Moyer was promoted to partner. Key names include Scot Hasselman in Washington DC and Michael Sanders in Century City, as well as Lisa Chiarini, Joshua Davis and Nicolas Barzoukas in Houston.

Known for its M&A capabilities, Skadden, Arps, Slate, Meagher & Flom LLP’s practice also has considerable expertise in IP, litigation and regulatory matters. In New York, Douglas Nemec has particular strength handling Hatch-Waxman patent litigation, while capital markets specialist Andrea Nicolas and M&A partner Paul Schnell often advise on high-profile transactional matters. In Boston, M&A group head Graham Robinson often assists life sciences clients with collaborations and related corporate issues. In Washington DC, Jennifer Bragg primarily acts for clients in FDA matters, including government investigations and enforcement issues.

WilmerHale’s team excels in litigation, as well as transactional and IP matters. Co-head Stuart Falber led advice to Apellis Pharmaceuticals on various corporate transactions, including stock financing and its IPO. Co-head Belinda Juran and Lia Der Marderosian advised Visterra on negotiations arising from a collaborative license agreement with Vir Biotechnology valued at $70m. On the litigation side, Lisa Pirozzolo has been representing CSL Behring in patent litigation brought by Bioverativ before the International Trade Commission (ITC) and the US District Court for the District of Delaware alleging patent infringement. Amy Wigmore continues to act for Bristol-Myers Squibb and Pfizer on Hatch-Waxman litigation brought against a number of generic drug companies regarding the Eliquis patent. Other key names include Steven Singer and Robert Gunther in New York, Bruce Manheim in Washington DC, and William Lee. All named partners are in Boston unless otherwise stated.

At Dentons, the group advises a diverse range of clients in the pharmaceutical industry, including manufacturers, distributors and service providers. In New Jersey, group co-head Jeffrey Baumel, Ilan Katz and Ira Kotel led advice to PharmAthene on a $100m merger with Altimmune. Dallas-based Robert Hanson has been representing Monsanto in various patent matters, including opposition proceedings. The group is also headed by Stephanie Seidman in San Diego and Peg Donahue Hall in Dallas.

Gibson, Dunn & Crutcher LLP’s department has experience acting on high-profile corporate and litigation matters. In San Francisco, department co-head Ryan Murr advised Rocket Pharma on its $270m merger with Inotek Pharmaceuticals. In Dallas, co-head Tracey Davies has been representing Sanofi in a number of Hatch-Waxman lawsuits arising from the company’s insulin diabetes products. In Los Angeles, Wayne Barsky has been representing Merck, Pfizer and EMD Serono in a patent infringement action brought by Biogen regarding the Rebif drug. The department, which is also led by New York-based co-head Daniel Thomasch, includes Jane Love and Robert Trenchard in New York and FDA regulatory expert Stephen Payne in Washington DC.

Kirkland & Ellis LLP’s group has notable strength in contentious matters, including product liability, False Claims Act and securities litigation. In Chicago, James Hurst successfully defended Abbott Laboratories in a False Claims Act case brought by a former employee. Jay Lefkowitz and Devora Allon represented Upsher-Smith Laboratories in a price-fixing class action regarding a generic blood pressure medication. Leora Ben-Ami, Thomas Fleming and Christopher Jagoe have been assisting Teva Pharmaceuticals and its subsidiary Actavis Laboratories with patent infringement litigation regarding the Neupro drug. On the corporate side, Peter Martelli advised Blackstone on its $6.1bn acquisition of TeamHealth. All partners are based in New York unless otherwise stated.

Morrison & Foerster LLP’s practice is known for its IP and litigation capabilities, as well as its expertise in cross-border corporate matters. The team has been assisting Bayer with various patent matters, including strategy, prosecution and licensing issues. It also assisted Temasek with its $800m investment in Verily Life Sciences and Alphabet. On the litigation side, the team has also been acting for Nevro on a patent infringement action brought against Boston Scientific regarding Nevro’s Senza spinal cord stimulation system. The practice is jointly headed by David Doyle in San Diego, Spencer Klein in New York and Janet Xiao in Palo Alto. Other clients include Washington University, DePuy Synthes and Alcon.

O'Melveny & Myers LLP’s practice is known for its strength in litigation matters. In New York, the well-regarded Lisa Pensabene, who leads on life sciences litigation, has considerable experience representing high-profile clients before all levels of court as first chair trial lawyer. Washington DC-based Seth Ray often advises clients on FDA regulatory issues arising from investigations and product liability litigation. In Los Angeles, Richard Goetz has notable experience handling product liability and mass tort litigation matters. Key names include Scott Elliott in San Francisco, Ross Galin in New York and Portia Ku in Silicon Valley.

The ‘thorough’ and ‘strong’ group at Weil, Gotshal & Manges LLP advises on the full gamut of corporate and litigation matters for clients in the life sciences arena, including antitrust and IP issues. Silicon Valley-based co-head Edward Reines successfully represented Stanford University in an appeal arising from an inventorship dispute with the Chinese University of Hong Kong regarding a revolutionary test for Down’s syndrome. ‘Extremely organized’ patent litigation partner Elizabeth Weiswasser, who has a ‘solid understanding of scientific issues’, has been representing Acorda Therapeutics in the company’s appeal to the Federal Circuit regarding a patent infringement judgment involving its Ampyra drug. IP partner Jeffrey Osterman and private equity partner Christopher Machera led advice to National Surgical Hospitals on its $760m acquisition by Surgery Partners. The group is also headed by Michael Epstein. Named partners are based in New York unless otherwise stated.

Wilson Sonsini Goodrich & Rosati’s practice handles the full range of technology and life sciences matters, including IP, corporate transactions and litigation. In Palo Alto, Lowell Segal often assists clients with strategic transactions and other corporate issues, including collaborations, licensing and asset purchases, while corporate partner Kenneth Clark primarily acts for clients in the biotechnology sector. Key contacts include patent expert Vern Norviel in San Francisco and litigator Douglas Carsten in San Diego.

International comparative guides

Giving the in-house community greater insight to the law and regulations in different jurisdictions.

Select Practice Area

Press releases

The latest news direct from law firms. If you would like to submit press releases for your firm, send an email request to

Legal Developments worldwide

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to

    Aziz Rahman considers the Ericsson bribery investigation and outlines how best to respond if you are investigated by more than one law enforcement agency
  • Sulphur Cap Ahead - Regulatory

    Sulphur Cap Ahead - Regulatory
  • GTDT Shipping - India

    Mr Shardul Thacker heads the shipping, oil and gas and banking practice group at Mulla & Mulla & Craigie Blunt & Caroe. Lloyd’s List ranked him third in their top 10 lawyers stating: “Highly regarded for his work in the liquefied natural gas sector, particularly for interesting and highly geared finance deals in relation to infrastructure projects, energy, ports and ships.” india_-_gtdt_shipping_

    The British Virgin Islands are rushing to pass by the end of December the new economic substance legislation to avoid the EU’s blacklist of tax haven jurisdictions.
  • Chambers Guides - Insurance 2018 - India

    India is a common-law jurisdiction. In general, Indian laws borrow heavily from, and are based on, English law. However, insurance law in India has certain unique features that deviate from English insurance law. The primary legislation of insurance law in India is the Insurance Act, 1938 (the “Insurance Act”) and the Insurance Rules, 1939 (the “Insurance Rules”).
  • AVELLUM advised largest Ukrainian brick manufacturer on restructuring and refinancing of its debt

    AVELLUM acted as the Ukrainian legal counsel to Private Joint Stock Company with Foreign Investments “Slobozhanska Budivelna Keramika” (“SBK ”) in connection with the restructuring and refinancing of SBK’s debt, valued at approximately EUR20 million. Atlas Advisors, an independent investment banking firm, acted as the exclusive financial advisor to the SBK’s shareholders in connection with the restructuring of the credit portfolio, attraction of financing for the debt’s refinancing, and buy-out of SBK’s shares.
  • AVELLUM advises on Ukraine’s USD2 billion Eurobond issue

    AVELLUM acted as the Ukrainian legal counsel to the Ministry of Finance of Ukraine on the USD2 billion sovereign Eurobond issue consisting of two tranches with 5.5 and 10-year tenor. J.P. Morgan Securities, Goldman Sachs, BNP Paribas, and Citigroup acted as joint lead managers on the transaction.
  • New Anti-Money Laundering Law

    The new anti-money laundering ( AML ) law of the UAE took effect at the end of October 2018. Containing features recommended by the Financial Action Task Force ( FATF ), the new law introduces subtle but important changes to the AML landscape in the UAE. 
  • Confidentiality Under Renewed Focus

    The UAE federal government has recently issued a raft of important legislation, addressing and in many ways updating areas of law that are key to businesses in the jurisdiction. Amongst this legislation is Federal Decree-Law 14 of 2018 concerning the central bank and the organisation of financial institutions and activities (the New Banking Law ) and Federal Decree-Law 20 of 2018 concerning anti-money laundering and anti-terrorism financing (the New AML Law ). Both the New Banking Law and the New AML Law repeal and replace the previous legislation on their respective subjects. Importantly, the New Banking Law and the New AML Law have together enhanced the protection afforded to confidential information under UAE law, in particular where financial and legal service providers and their customers and clients are concerned. 
  • Israel Chapter in The Virtual Currency Regulation Review

    Earlier this year, the Israel Tax Authority (ITA) issued two circulars, one on the taxation of digital tokens and the second addressing the taxation of utility tokens in initial coin offerings (ICOs). Additionally, in March, the Israel Securities Authority (ISA) released a detailed interim report by the Committee for the Regulation of Public Offerings of Decentralized Cryptocurrency Coins (Report) (with a follow-up report due to come out around October 2018). Moreover, it is expected that before the end of 2018, legislation will come into force that for the first time will see Israeli primary legislation define virtual currencies as financial assets and mandate licensing for related services, as is later discussed in detail.

Press Releases worldwide

The latest news direct from law firms. If you would like to submit press releases for your firm, send an email request to